Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4ZS8M)

Drug Name
Nefazodone Drug Info
Synonyms
Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
Therapeutic ClassAntidepressants
Cross-matching ID
PubChem CID
4449
ChEBI ID
CHEMBL623
CAS Number
CAS 83366-66-9
TTD Drug ID
D0X7DE
VARIDT Drug ID
DR00468
INTEDE Drug ID
DR1135
ACDINA Drug ID
D00460

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Natural killer cell mediated cytotoxicity -1.60 4.95e-2 99/131 (75.57%) MICA;CSF2;HLA-E;...
Human immunodeficiency virus 1 infection -1.62 4.07e-2 189/212 (89.15%) CASP9;IFNB1;MAPK10;...
Lipid and atherosclerosis -1.62 4.24e-2 190/215 (88.37%) GSK3B;NCF4;RXRB;...
T cell receptor signaling pathway -1.66 3.02e-2 93/104 (89.42%) GSK3B;LCP2;RELA;...
Toxoplasmosis -1.69 2.28e-2 103/112 (91.96%) RELA;LDLR;HSPA1L;...
Ribosome -1.71 2.09e-2 113/158 (71.52%) RPS24;RPS15A;RPSA;...
Lysosome -1.71 2.19e-2 115/128 (89.84%) NEU1;PLA2G15;TPP1;...
Glioma -1.71 2.31e-2 67/75 (89.33%) PIK3CD;MAPK3;EGF;...
TNF signaling pathway -1.73 1.93e-2 103/112 (91.96%) PIK3CD;MAPK3;IL18R1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.74 2.05e-2 79/89 (88.76%) RELA;TRAF6;PIK3R3;...
Bladder cancer -1.75 1.61e-2 40/41 (97.56%) MAPK3;EGF;MAP2K2;...
Mineral absorption -1.75 1.72e-2 48/60 (80%) SLC5A1;MT2A;ATP1A1;...
Intestinal immune network for IgA production -1.78 1.56e-2 38/48 (79.17%) MADCAM1;CD86;CXCR4;...
Mitophagy -1.84 7.93e-3 56/68 (82.35%) MAPK10;TFE3;HRAS;...
Inflammatory bowel disease -1.87 3.22e-3 58/65 (89.23%) IL18R1;SMAD3;IL1B;...
Epithelial cell signaling in Helicobacter pylori infect... -1.88 3.51e-3 62/70 (88.57%) RELA;ATP6V1G1;CDC42;...
Th17 cell differentiation -1.91 1.29e-3 95/107 (88.79%) MAPK3;FOS;SMAD3;...
Rheumatoid arthritis -1.93 0.00e+0 78/93 (83.87%) ATP6V1F;ATP6V0C;TCIRG1;...
Antigen processing and presentation -1.98 0.00e+0 60/78 (76.92%) CD8B;CIITA;B2M;...
Asthma -1.99 0.00e+0 25/31 (80.65%) CD40;HLA-DPA1;HLA-DPB1;...
Graft-versus-host disease -1.99 0.00e+0 32/42 (76.19%) HLA-F;CD80;HLA-E;...
IL-17 signaling pathway -2.06 0.00e+0 84/94 (89.36%) GSK3B;IL17RA;RELA;...
Autoimmune thyroid disease -2.08 0.00e+0 46/53 (86.79%) HLA-F;CD40LG;CD80;...
Th1 and Th2 cell differentiation -2.09 0.00e+0 80/92 (86.96%) JAK1;MAPK11;LCK;...
Type I diabetes mellitus -2.16 0.00e+0 38/43 (88.37%) HLA-F;GAD2;CD80;...
Allograft rejection -2.30 0.00e+0 32/38 (84.21%) HLA-F;CD40LG;CD80;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H